Intravenous Immunoglobulin and Guillain-Barré Syndrome
Authors:
- 1 January 2005
- journal article
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 29 (3) , 281-288
Abstract
Guillain-Barré syndrome (GBS) is a relatively common, potentially lethal disease of a presumed autoimmune origin, known to cause a progressive flaccid paralysis. The treatment of GBS consists of both supportive and immunomodulatory treatments, among which intravenous immunoglobulin (IVIg) and plasma exchange (PE) are considered most effective. A number of randomized, controlled studies have shown IVIg to be at least as effective as PE in the treatment of GBS, and in some cases superior. Moreover, IVIg has been found to be safer than PE, having a lower frequency of multiple complications. IVIg has also been found to be both effective and safe in the treatment of pediatric patients with GBS. Thus, its efficacy, safety, and availability make IVIg the treatment of choice in many patients with GBS.Keywords
This publication has 19 references indexed in Scilit:
- Plasmapheresis Treatment in Guillain–Barré Syndrome: Potential Benefit over IVIg in Patients with Axonal InvolvementTherapeutic Apheresis and Dialysis, 2004
- The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profilePharmacology & Therapeutics, 2004
- Intravenous Immunoglobulin in Autoimmune Neuromuscular DiseasesJAMA, 2004
- Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathiesBrain, 2004
- Immune mediated neuropathiesJournal of Neurology, 2004
- Guillain-Barr?? SyndromeDrugs, 2004
- Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3 days versus 6 daysJournal of Neurology, Neurosurgery & Psychiatry, 2001
- Campylobacter jejuni infections and anti‐GM1 antibodies in guillain‐barré syndromeAnnals of Neurology, 1996
- Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndromeNeurology, 1996
- Intravenous Immunoglobulin Treatment in Children with Guillain-Barre SyndromeScandinavian Journal of Infectious Diseases, 1995